Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of NPH insulin and inhaled human insulin represents a treatment approach for diabetes mellitus that pairs an intermediate-acting injectable insulin with a rapid-acting inhaled insulin formulation.\n\nNPH insulin (Neutral Protamine Hagedorn) serves as the basal insulin component, providing background insulin coverage for 12-18 hours. It typically peaks at 4-12 hours after injection and helps control blood glucose between meals and overnight[4].\n\nThe inhaled human insulin component (brand name Afrezza, formerly Exubera) is a dry powder form of rapid-acting insulin delivered by oral inhalation[2]. It starts working within 10-15 minutes, peaks at 35-45 minutes, and has a duration of 1.5-3 hours[4]. This rapid action makes it suitable for controlling mealtime blood glucose spikes.\n\n## Clinical Evidence\n\nClinical trials have demonstrated that this combination can provide effective glycemic control. In patients with type 1 diabetes, studies showed that inhaled insulin before meals plus ultralente insulin at night provided comparable glycemic control to conventional insulin regimens[3]. Similarly, in type 2 diabetes, the combination of inhaled insulin with basal insulin has shown effectiveness in controlling blood glucose levels[5].\n\n## Administration\n\nThe NPH insulin is administered subcutaneously, typically once or twice daily. The inhaled insulin is administered at the beginning of meals using a specialized inhaler device[1]. This combination reduces, but does not eliminate, the need for injections in patients with diabetes.\n\n## Safety Considerations\n\nCommon side effects of inhaled insulin include hypoglycemia, cough, throat pain, and potential decreases in pulmonary function[2][6]. Pulmonary function should be monitored during treatment, with baseline spirometry followed by repeat testing at six months and one year, with yearly follow-up thereafter[2]. Inhaled insulin is contraindicated in patients with chronic pulmonary diseases such as asthma and COPD[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NPH insulin + inhaled human insulin.